Evolus, Inc. (EOLS)
Largest Insider Buys in Sector
EOLS Stock Price History Chart
EOLS Stock Performance
About Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Activity of Evolus, Inc.
Over the last 12 months, insiders at Evolus, Inc. have bought $0 and sold $10.03M worth of Evolus, Inc. stock.
On average, over the past 5 years, insiders at Evolus, Inc. have bought $3.4M and sold $18.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 174,967 shares for transaction amount of $1.3M was made by Malik Vikram (director) on 2023‑08‑15.
List of Insider Buy and Sell Transactions, Evolus, Inc.
| 2024-09-06 | Sale | Chief Financial Officer | 3,276 0.0053% | $14.98 | $49,074 | +12.75% | ||
| 2024-08-30 | Sale | Chief Marketing Officer | 5,631 0.0089% | $15.85 | $89,251 | +4.00% | ||
| 2024-06-06 | Sale | See Remarks | 175,940 0.2852% | $12.59 | $2.21M | +25.24% | ||
| 2024-06-05 | Sale | See Remarks | 155,278 0.2465% | $12.92 | $2.01M | +19.09% | ||
| 2024-06-04 | Sale | See Remarks | 140,214 0.2217% | $12.73 | $1.78M | +20.37% | ||
| 2024-06-03 | Sale | director | 7,500 0.0119% | $12.96 | $97,203 | +18.53% | ||
| 2024-05-14 | Sale | director | 6,718 0.0106% | $12.60 | $84,654 | +14.93% | ||
| 2024-05-13 | Sale | director | 28,000 0.0459% | $12.93 | $362,012 | +13.96% | ||
| 2024-05-13 | Sale | director | 3,643 0.0059% | $12.72 | $46,356 | +13.96% | ||
| 2024-05-10 | Sale | See Remarks | 16,051 0.0256% | $12.72 | $204,127 | +10.12% | ||
| 2024-05-10 | Sale | See Remarks | 3,441 0.0055% | $12.72 | $43,761 | +10.12% | ||
| 2024-05-10 | Sale | Chief Financial Officer | 2,423 0.0039% | $12.72 | $30,814 | +10.12% | ||
| 2024-03-27 | Sale | See Remarks | 6,236 0.01% | $13.86 | $86,431 | -5.14% | ||
| 2024-03-19 | Sale | See Remarks | 96,566 0.1564% | $13.92 | $1.34M | -4.90% | ||
| 2024-03-19 | Sale | See Remarks | 27,603 0.0447% | $13.92 | $384,350 | -4.90% | ||
| 2024-03-19 | Sale | Chief Financial Officer | 5,672 0.0092% | $13.92 | $78,978 | -4.90% | ||
| 2024-02-22 | Sale | See Remarks | 7,706 0.0134% | $13.08 | $100,804 | +4.41% | ||
| 2024-02-22 | Sale | See Remarks | 1,821 0.0032% | $13.08 | $23,821 | +4.41% | ||
| 2024-02-22 | Sale | Chief Financial Officer | 1,821 0.0032% | $13.08 | $23,821 | +4.41% | ||
| 2024-01-30 | Sale | director | 11,931 0.0211% | $13.14 | $156,733 | +5.05% |
Insider Historical Profitability
| Malik Vikram | director | 246514 0.3907% | $16.48 | 4 | 7 | <0.0001% |
| GILL DAVID N | director | 33964 0.0538% | $16.48 | 2 | 3 | +8.2% |
| Medytox Inc. | 3381326 5.3591% | $16.48 | 15 | 9 | <0.0001% | |
| Jafar Michael M. | See Remarks | 174851 0.2771% | $16.48 | 1 | 1 | <0.0001% |
| BLANK SIMONE | 54881 0.087% | $16.48 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Perceptive Advisors | $80.55M | 9.19 | 5.75M | +45.17% | +$25.07M | 0.05 | |
| Tang Capital Management, LLC | $58.06M | 6.62 | 4.15M | +33.9% | +$14.7M | 0.22 | |
| BlackRock | $45.65M | 5.21 | 3.26M | -2.35% | -$1.1M | <0.01 | |
| Morgan Stanley | $42.6M | 4.86 | 3.04M | +17.81% | +$6.44M | <0.01 | |
| Nantahala Capital Management Llc | $40.75M | 4.65 | 2.91M | 0% | +$0 | 1.9 |